{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:31:16Z","timestamp":1783488676503,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["General Hospital Psychiatry"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.genhosppsych.2024.06.005","type":"journal-article","created":{"date-parts":[[2024,6,12]],"date-time":"2024-06-12T18:48:52Z","timestamp":1718218132000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system"],"prefix":"10.1016","volume":"90","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuezhong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guibin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.genhosppsych.2024.06.005_bb0005","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s40265-017-0770-9","article-title":"Valbenazine: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.genhosppsych.2024.06.005_bb0010","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1517\/13543784.2015.1029573","article-title":"Valbenazine granted breakthrough drug status for treating tardive dyskinesia","volume":"24","author":"M\u00fcller","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.genhosppsych.2024.06.005_bb0015","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.NU18041BR3C","article-title":"FDA-approved medications to treat tardive dyskinesia","volume":"81","author":"McEvoy","year":"2019","journal-title":"J Clin Psychiatry"},{"issue":"26","key":"10.1016\/j.genhosppsych.2024.06.005_bb0020","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMp1704898","article-title":"Efficient trial design - FDA approval of valbenazine for tardive dyskinesia","volume":"376","author":"Davis","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.genhosppsych.2024.06.005_bb0025","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4088\/JCP.17m11777","article-title":"The effects of Valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study","volume":"78","author":"Factor","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.genhosppsych.2024.06.005_bb0030","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: a mixed picture","volume":"18","author":"Factor","year":"2019","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.genhosppsych.2024.06.005_bb0035","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive dyskinesia prevalence in the period of second-generation antipsychotic use: a meta-analysis","volume":"78","author":"Carbon","year":"2017","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.1016\/j.genhosppsych.2024.06.005_bb0040","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2017.16091037","article-title":"KINECT 3: a phase 3 randomized, double-blind, placebo-controlled trial of Valbenazine for tardive dyskinesia","volume":"174","author":"Hauser","year":"2017","journal-title":"Am J Psychiatry"},{"issue":"12","key":"10.1016\/j.genhosppsych.2024.06.005_bb0045","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/mds.26330","article-title":"NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study","volume":"30","author":"O\u2019Brien","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0050","first-page":"13","article-title":"Neurological adverse events associated with esketamine: a disproportionality analysis for signal detection leveraging the FDA adverse event reporting system","author":"Guo","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0055","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/3695101","article-title":"Fournier gangrene associated with sodium-glucose Cotransporter-2 inhibitors: a pharmacovigilance study with data from the U.S. FDA adverse event reporting system","volume":"2020","author":"Hu","year":"2020","journal-title":"J Diabetes Res"},{"issue":"11","key":"10.1016\/j.genhosppsych.2024.06.005_bb0060","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.750108","article-title":"Kidney injury following ibuprofen and acetaminophen: a real-world analysis of post-marketing surveillance data","volume":"12","author":"Shao","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.766125","article-title":"Safety of SGLT2 inhibitors: a pharmacovigilance study from 2013 to 2021 based on FAERS","volume":"12","author":"Zhou","year":"2021","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.genhosppsych.2024.06.005_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.genhosppsych.2024.06.005_bb0080","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.genhosppsych.2024.06.005_bb0085","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"10.1016\/j.genhosppsych.2024.06.005_bb0090","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.genhosppsych.2024.06.005_bb0100","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/jcpt.13024","article-title":"Time-to-onset analysis of amiodarone-associated thyroid dysfunction","volume":"45","author":"Kinoshita","year":"2020","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.genhosppsych.2024.06.005_bb0105","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1212\/WNL.0b013e31829d86b6","article-title":"Evidence-based guideline: treatment of tardive syndromes: report of the guideline development Subcommittee of the American Academy of neurology","volume":"81","author":"Bhidayasiri","year":"2013","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.genhosppsych.2024.06.005_bb0110","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.encep.2015.12.021","article-title":"Prevention and treatment of tardive dyskinesia caused by antipsychotic drugs","volume":"42","author":"Seigneurie","year":"2016","journal-title":"Encephale"},{"issue":"3","key":"10.1016\/j.genhosppsych.2024.06.005_bb0115","article-title":"Miscellaneous treatments for antipsychotic-induced tardive dyskinesia","volume":"3","author":"Soares-Weiser","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jns.2018.02.010","article-title":"Updating the recommendations for treatment of tardive syndromes: a systematic review of new evidence and practical treatment algorithm","volume":"389","author":"Bhidayasiri","year":"2018","journal-title":"J Neurol Sci"},{"issue":"11","key":"10.1016\/j.genhosppsych.2024.06.005_bb0125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/pcn.13455","article-title":"Efficacy and safety of valbenazine in Japanese patients with tardive dyskinesia: a multicenter, randomized, double-blind, placebo-controlled study (J-KINECT)","volume":"76","author":"Horiguchi","year":"2022","journal-title":"Psychiatry Clin Neurosci"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0130","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/DDDT.S133205","article-title":"Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Solmi","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.genhosppsych.2024.06.005_bb0135","article-title":"Use of valbenazine in a 54-year-old female with severe tardive dyskinesia","volume":"12","author":"Yee","year":"2020","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.genhosppsych.2024.06.005_bb0140","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/gps.5218","article-title":"The effects of valbenazine on tardive dyskinesia in older and younger patients","volume":"35","author":"Sajatovic","year":"2020","journal-title":"Int J Geriatr Psychiatry"},{"issue":"3","key":"10.1016\/j.genhosppsych.2024.06.005_bb0145","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/YCO.0000000000000491","article-title":"Antipsychotic-induced tardive dyskinesia: update on epidemiology and management","volume":"32","author":"Widschwendter","year":"2019","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.genhosppsych.2024.06.005_bb0150","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jns.2017.11.019","article-title":"Clinical management of tardive dyskinesia: five steps to success","volume":"383","author":"Citrome","year":"2017","journal-title":"J Neurol Sci"},{"issue":"9","key":"10.1016\/j.genhosppsych.2024.06.005_bb0155","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14737175.2017.1361322","article-title":"Antipsychotic-induced tardive dyskinesia: from biological basis to clinical management","volume":"17","author":"Salem","year":"2017","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1016\/j.genhosppsych.2024.06.005_bb0160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ajhp\/zxz299","article-title":"Valbenazine and deutetrabenazine: vesicular monoamine transporter 2 inhibitors for tardive dyskinesia","volume":"77","author":"Khorassani","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"10.1016\/j.genhosppsych.2024.06.005_bb0165","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1358\/dot.2016.52.12.2570977","article-title":"Valbenazine for the treatment of tardive dyskinesia","volume":"52","author":"Barquero","year":"2016","journal-title":"Drugs Today (Barc)"}],"container-title":["General Hospital Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324001440?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163834324001440?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T17:43:34Z","timestamp":1725990214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163834324001440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":33,"alternative-id":["S0163834324001440"],"URL":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.06.005","relation":{},"ISSN":["0163-8343"],"issn-type":[{"value":"0163-8343","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mining of neurological adverse events associated with valbenazine: A post-marketing analysis based on FDA adverse event reporting system","name":"articletitle","label":"Article Title"},{"value":"General Hospital Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.genhosppsych.2024.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}